



Drug Prior Authorization Form Tecentriq (Atezolizumab)

The purpose of this form is to obtain information required to assess your drug claim.

IMPORTANT: Please answer all questions. Your claim assessment will be delayed if this form is incomplete or contains errors.

Any costs incurred for the completion of this form are the responsibility of the plan member/patient.

Canada Life recognizes and respects the importance of privacy. Personal information collected is used for the purposes of assessing eligibility for this drug and for administering the group benefits plan. For a copy of our Privacy Guidelines, or if you have questions about Canada Life’s personal information policies and practices (including with respect to service providers), refer to www.canadalife.com or write to Canada Life’s Chief Compliance Officer.

I authorize Canada Life, any healthcare provider, my plan administrator, any insurance or reinsurance company, administrators of government benefits or patient assistance programs or other benefits programs, other organizations, or service providers working with Canada Life or any of the above, located inside or outside Canada, to exchange personal information when relevant and necessary for these purposes. I understand that personal information may be subject to disclosure to those authorized under applicable law within or outside Canada.

I acknowledge that the personal information is needed to assess eligibility for this drug and to administer the group benefits plan. I acknowledge that providing consent will help Canada Life to assess my claim and that refusing to consent may result in delay or denial of my claim. Canada Life reserves the right to audit the information provided on this form at any time and this consent extends to any audit of my claim. This consent may be revoked by me at any time by sending written instruction to that effect.

I also consent to the use of my personal information for Canada Life and its affiliates’ internal data management and analytics purposes.

If the patient is a person other than myself, I confirm that the patient has given their consent to provide their personal information and for Canada Life to use and disclose it as set out above.

I certify that the information given below is true, correct, and complete to the best of my knowledge. Failure to provide true, correct and complete information on this form could result in revocation of any approval decision, a requirement to repay paid claims or other appropriate action.

Plan Member’s signature: _____

Date: _____

Form Completion Instructions:

1. Complete “Patient Information” sections.
2. Have the prescribing physician complete the “Physician Information” sections.
3. Send all pages of the completed form to us by mail, fax or email as noted below.

Note: As email is not a secure medium, any person with concerns about their prior authorization form/medical information being intercepted by an unauthorized party is encouraged to submit their form by other means.

Mail to: The Canada Life Assurance Company
Drug Claims Management
PO Box 6000
Winnipeg MB R3C 3A5

Fax to: The Canada Life Assurance Company
Fax 1-204-946-7664
Attention: Drug Claims Management

Email to: cldrug.services@canadalife.com
Attention: Drug Claims Management

For additional information regarding Prior Authorization and Health Case Management, please visit our Canada Life website at www.canadalife.com or contact Group Customer Contact Services at 1-800-957-9777. Deaf or hard of hearing and require access to a telecommunications relay service? Please contact us at 711 for TTY to Voice or 1-800-855-0511 for Voice to TTY.

(Continued on next page)

**Patient Information
Tecentriq (Atezolizumab)**

Plan Member Information – Complete all sections of this page (please print)

Plan Member:		Patient Name:	
Plan Name:	Plan Number:	Plan Member ID Number:	
Patient Date of Birth (DD/MM/YYYY):	Address (number, street, city, province, postal code):		

Please indicate preferred contact number and if there are any times when telephone contact with you about your claim would be most convenient.

May we contact you by email? (Note that some correspondence may still need to be sent by regular mail).

Yes No If yes, please provide email address: _____

Tell us if you have been on this drug before

Is the patient currently on, or previously been on this drug? Yes No

If Yes, a) indicate start date (DD/MM/YYYY): _____

b) coverage provided by: _____

(if coverage is not provided by Canada Life please provide pharmacy print-out showing purchase of this drug)

Tell us if you have coverage with any other benefits plan

Does the patient have drug coverage under any other group benefits plan? Yes No

If Yes, name of other Insurance Company: _____

If other plan is with Canada Life, tell us the plan and ID number: _____

Name of plan member: _____

Relationship to patient: _____

Provide details and attach documentation of acceptance or decline:

Tell us about any Provincial or other coverage you may have

Does the patient have coverage under a provincial program or from any other source? Yes No

If Yes, name of program or other source: _____

Provide details and attach documentation of acceptance or decline: _____

Is the patient currently receiving disability benefits for the condition for which this drug has been prescribed? Yes No

Tell us about any Patient Assistance Program you might be enrolled in

Has the patient enrolled in the patient assistance program for this drug? Yes No

If Yes, please provide the following information:

1. Patient assistance program patient ID Number: _____

2. Patient assistance program contact person name and phone number:

Contact Name: _____ Phone Number: _____

(Continued on next page)

Physician Information Tecentriq (Atezolizumab)

Note to Physician: In order to assess a patient's claim for this drug, we require detailed information on the patient's prescription drug history as requested below.

Attach extra information if necessary. GENETIC TEST RESULTS ARE NOT REQUIRED

Physician's Information (please print)

Name of prescribing physician: _____

Specialty: _____

Address (number, street, city, province, postal code): _____

Telephone Number (including area code): _____	Fax Number (including area code): _____
---	---

1. Is this drug being prescribed in accordance with approved Health Canada indications¹?

Yes, complete questions 1 – 8 and Physician's Information

No, condition not approved by Health Canada: _____

Complete questions 1 -8 and Off-label use

¹Approved Health Canada Indications and Clinical Use for Tecentriq

Breast Cancer

¹In combination with nab-paclitaxel, for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression $\geq 1\%$, and who have not received prior chemotherapy for metastatic disease.

Hepatocellular Carcinoma

¹In combination with bevacizumab, for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy.

Lung Cancer

NSCLC

¹In combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic non-squamous NSCLC.

¹In combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations.

¹For the treatment of adult patients with locally advanced or metastatic NSCLC with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have disease progression on a therapy for these aberrations prior to receiving TECENTRIQ.

ES-SCLC

¹In combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

Physician Information Tecentriq (Atezolizumab)

Physician's Information (continued) (please print)

Urothelial Carcinoma

¹For the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who:

Have disease progression during or following platinum containing chemotherapy; or

Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Other (approved by Health Canada): _____

Complete questions 1-8 and Other condition (Health Canada approved)

2. Prescribed dosage and regimen:

840 mg IV every 2 weeks

1200 mg IV every 3 weeks

1680 mg IV every 4 weeks

Other (please specify):

Provide rationale: _____

3. Please provide date of initial diagnosis (MM/YYYY): _____

4. What is the patient's current ECOG score? _____

5. What is the anticipated duration of treatment with this drug? _____

6. Where will treatment be administered? Home Physician's Office Private clinic Hospital in-patient Hospital out-patient

7. Please provide medical rationale why this drug has been prescribed instead of an alternate drug in the same therapeutic class.

Genetic test results are not required.

8. Drug and Treatment History – **must be completed for every request.**

Drug(s) and Treatment(s) past and present	Dosing Regimen	Start Date (DD/MM/YYYY)	End Date (DD/MM/YYYY)	Clinical Results/Outcome
				<input type="checkbox"/> Failure <input type="checkbox"/> Intolerance <input type="checkbox"/> Other Clinical details: _____ _____
				<input type="checkbox"/> Failure <input type="checkbox"/> Intolerance <input type="checkbox"/> Other Clinical details: _____ _____
				<input type="checkbox"/> Failure <input type="checkbox"/> Intolerance <input type="checkbox"/> Other Clinical details: _____ _____

Physician Information Tecentriq (Atezolizumab)

Physician's Information (*continued*) (please print)

Breast cancer – unresectable, locally advanced or metastatic, in combination - Genetic test results are not required

Has the patient had previous chemotherapy for metastatic breast cancer? Yes No

Will Tecentriq be used in combination with nab-paclitaxel (Abraxane)? Yes No

Hepatocellular Carcinoma, first line – Genetic test results are not required

Has the patient received prior systemic therapy for unresectable or metastatic hepatocellular carcinoma? Yes No

Will Tecentriq be used in combination with bevacizumab? Yes No

Does the patient require coverage for bevacizumab? Yes No

If yes, a separate prior authorization form is not required. Please indicate the prescribed dosage of bevacizumab:

Non-small cell lung cancer – first line - in combination – Genetic test results are not required

Has the patient received prior systemic chemotherapy treatment for metastatic non-squamous non-small cell lung cancer? Yes No

Will Tecentriq be used in combination with other agents? Yes No

If yes, please indicate which agents

Bevacizumab, paclitaxel and carboplatin

Nab-paclitaxel and carboplatin

Does the patient require coverage for bevacizumab? Yes No

If yes, separate prior authorization form is not required. Please indicate the prescribed dosage for bevacizumab: _____

Non-small cell lung cancer – second line – Genetic test results are not required

Has the patient been diagnosed with advanced or metastatic NSCLC? Yes No

Has the patient been treated with platinum-containing chemotherapy for advanced or metastatic disease? Yes No

If a suitable candidate, has the patient trialed and failed at least one tyrosine kinase inhibitors (TKIs)? Yes No Not Applicable

Will the patient be treated with Tecentriq as monotherapy? Yes No

Small-Cell Lung Cancer – first line – in combination – Genetic test results are not required

Will Tecentriq be used as first line treatment for ES-SCLC? Yes No

Will Tecentriq be used in combination with carboplatin and etoposide? Yes No

Physician Information Tecentriq (Atezolizumab)

Physician's Information (*continued*) (please print)

Urothelial Carcinoma – Genetic test results are not required

Has the patient been diagnosed with locally advanced or metastatic urothelial cancer? Yes No

If No, Date when advanced or metastatic disease was confirmed: _____ (DD/MM/YYYY)

Has the patient received platinum-containing chemotherapy for locally advanced or metastatic urothelial cancer? Yes No

If yes, did patient have disease progression during or after treatment? Yes No

Did the patient previously receive platinum-containing chemotherapy as adjuvant or neoadjuvant therapy? Yes No

If yes, did patient have disease progression within 12 months of therapy? Yes No

Will the patient be treated with Tecentriq as monotherapy? Yes No

Other condition (Health Canada approved) – Genetic test results are not required

Please provide any relevant information related to the disease and attach supporting documentation.

Renewal Request – Genetic test results are not required

Start date of treatment (MM/YYYY): _____

Has the patient had disease progression while on Tecentriq? Yes No

Off-label use – Genetic test results are not required

Questions 1- 8 must be completed.

Is there clinical evidence supporting the off-label use of this drug? Yes No

Provide clinical literature/studies to support the request for off-label use, such as:

- At least two Phase II or two Phase III clinical trials showing consistent results of efficacy; and
- Published recommendations in evidence-based guidelines supporting its use.

Provide medical rationale why Tecentriq has been prescribed off-label instead of an alternate drug with an approved indication for this condition.

Provide any pertinent medical history or information to support this off-label request.

If this is a renewal request, provide documentation showing treatment efficacy since previous request.



Physician Information Tecentriq (Atezolizumab)

Note for Physician: To be eligible for reimbursement, Canada Life may require your patient to purchase a drug requiring prior authorization from a pharmacy designated by Canada Life. If applicable, a health case manager will contact you with further information.

I certify that the information provided is true, correct, and complete.

Physician's Signature: _____ Date: _____

License Number: _____

It is important to provide the requested information in detail to help avoid delay in assessing claims for the above drug. This form may be subject to audit. The completed form can be returned to Canada Life by mail, fax, or email.

Note: As email is not a secure medium, any person with concerns about their prior authorization form/medical information being intercepted by an unauthorized party is encouraged to submit their form by other means.

**Mail to: The Canada Life Assurance Company
Drug Claims Management
PO Box 6000
Winnipeg MB R3C 3A5**

**Fax to: The Canada Life Assurance Company
Fax 1-204-946-7664
Attention: Drug Claims Management**

**Email to: cldrug.services@canadalife.com
Attention: Drug Claims Management**